NIH confirms cut-back in Indian trials but large sponsors hope for reform
This article was originally published in Scrip
In what is probably one of its more lucid responses on the scrapping of a large number of clinical studies in India, the US National Institutes of Health (NIH), the largest source of funding for medical research in the world, has said that the Indian trials were stopped mainly because of the country's evolving trial regulations.
You may also be interested in...
A rise in bureaucracy and increased liability for clinical trial sponsors have impacted the popularity of India as a location for pharmaceutical companies’ clinical studies. Trialtrove’s Deborah Jeanfavre examines the data, which show a continuing decrease in new industry-sponsored trials starting in India over the past five years.
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.